Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly

Modern Rheumatology

Volumn 23, Issue 5, 2013, Pages 994-1000

  Mochizuki, Takeshi ^a   Momohara, Shigeki ^b   Yano, Koichio ^b   Shirahata, Toshikatsu ^c   Ikari, Katsunori ^b  

^a National Hospital Organization   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Chibanishi General Hospital   (Japan)

Author keywords

Disease activity score; Etanercept; Remission; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; STROMELYSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART PALPITATION; HUMAN; INJECTION SITE REACTION; JAPANESE; MALE; PAIN; PRIORITY JOURNAL; PRURITUS; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885183347     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0790-y     Document Type: Article

References (21)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440.
2. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007;21:27-42.
3. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-94.
4. Harigai M. Is the combination of etanercept and methotrexate safe as a means of treating rheumatoid arthritis? Method for analysis of survey data from all etanercept-treated cases. Rheumatology. 2008;39:21-6.
5. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Post-marketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898-906.
6. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2011 [Epub ahead of print].
7. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-9.
8. Lipsky PE, van der Heidge DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-602.
9. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-93.
10. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443-50.
11. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthr Rheum. 2004;50:353-63.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum. 1988;16:65-7.
13. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum. 1995;38:44-8.
14. Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16:63-7.
15. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum. 1996;39:34-40.
16. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simple disease activity index for rheumatoid arthritis in clinical practice. Rheumatology. 2003;42:244-57.
17. Van der Heijde D. Radiographic progression in rheumatoid arthritis: dose it reflect outcome? Does it reflect treatment? Ann Rheum Dis. 2001;60 suppl3:iii 47-50.
18. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A study of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;240:253-9.
19. Moreland LW, Schiff MH, Baumagartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled study. Ann Intern Med. 1999;130:478-86.
20. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837-46.
21. Felson DT, Anderson JJ, Boers M, Bonbardier C, Furst D, Gold smith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthr Rheum. 1995;6:727-35.